Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner - Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner - Johnson & Johnson (NYSE:JNJ)

The U.S. Food and Drug Administration (FDA) on Tuesday approved a new, simplified monthly dosing schedule for Johnson & Johnson’s (NYSE:JNJ) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj). When administered in combination with oral Lazcluze (lazertinib) for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), monthly dosing delivers consistent outcomes with the previously…

J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC

J&J has received the US FDA approval for a new monthly dosing schedule for the combination therapy Rybrevant Faspro to treat patients with advanced, EGFR-mutated NSCLC.

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted Therapy that can be Administered Once a Month - Life Sciences British Columbia

Johnson & Johnson, announced the U.S. (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™.

FDA OKs Once-Monthly Subcutaneous Amivantamab Dose in EGFR+ NSCLC

Monthly dosing of subcutaneous amivantamab may confer consistent outcomes with the previously approved biweekly dosing schedule in EGFR-mutant NSCLC.